448 related articles for article (PubMed ID: 25667284)
1. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
Den RB; Yousefi K; Trabulsi EJ; Abdollah F; Choeurng V; Feng FY; Dicker AP; Lallas CD; Gomella LG; Davicioni E; Karnes RJ
J Clin Oncol; 2015 Mar; 33(8):944-51. PubMed ID: 25667284
[TBL] [Abstract][Full Text] [Related]
2. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.
Den RB; Feng FY; Showalter TN; Mishra MV; Trabulsi EJ; Lallas CD; Gomella LG; Kelly WK; Birbe RC; McCue PA; Ghadessi M; Yousefi K; Davicioni E; Knudsen KE; Dicker AP
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1038-1046. PubMed ID: 25035207
[TBL] [Abstract][Full Text] [Related]
3. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
4. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
5. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
6. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.
Freedland SJ; Choeurng V; Howard L; De Hoedt A; du Plessis M; Yousefi K; Lam LL; Buerki C; Ra S; Robbins B; Trabulsi EJ; Shah NL; Abdollah F; Feng FY; Davicioni E; Dicker AP; Karnes RJ; Den RB
Eur Urol; 2016 Oct; 70(4):588-596. PubMed ID: 26806658
[TBL] [Abstract][Full Text] [Related]
7. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Yousefi K; Davicioni E; Ghadessi M; Johnson MH; Sundi D; Tosoian JJ; Han M; Humphreys EB; Partin AW; Walsh PC; Trock BJ; Schaeffer EM
Eur Urol; 2016 Mar; 69(3):496-504. PubMed ID: 25922274
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk.
Ross AE; Den RB; Yousefi K; Trock BJ; Tosoian J; Davicioni E; Thompson DJ; Choeurng V; Haddad Z; Tran PT; Trabulsi EJ; Gomella LG; Lallas CD; Abdollah F; Feng FY; Klein EA; Dicker AP; Freedland SJ; Karnes RJ; Schaeffer EM
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):277-82. PubMed ID: 27136742
[TBL] [Abstract][Full Text] [Related]
9. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
[TBL] [Abstract][Full Text] [Related]
10. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
11. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.
Karnes RJ; Bergstralh EJ; Davicioni E; Ghadessi M; Buerki C; Mitra AP; Crisan A; Erho N; Vergara IA; Lam LL; Carlson R; Thompson DJ; Haddad Z; Zimmermann B; Sierocinski T; Triche TJ; Kollmeyer T; Ballman KV; Black PC; Klee GG; Jenkins RB
J Urol; 2013 Dec; 190(6):2047-53. PubMed ID: 23770138
[TBL] [Abstract][Full Text] [Related]
12. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting.
Howard LE; Zhang J; Fishbane N; Hoedt AM; Klaassen Z; Spratt DE; Vidal AC; Lin D; Hitchins MP; You S; Freeman MR; Yamoah K; Davicioni E; Freedland SJ
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):419-428. PubMed ID: 31844180
[TBL] [Abstract][Full Text] [Related]
13. External validation of genomic classifier-based risk-stratification tool to identify candidates for adjuvant radiation therapy in patients with prostate cancer.
Lee DI; Shahait M; Dalela D; Keeley J; Lal P; Vapiwala N; Abdollah F
World J Urol; 2021 Sep; 39(9):3217-3222. PubMed ID: 33388922
[TBL] [Abstract][Full Text] [Related]
14. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
15. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features.
Karnes RJ; Choeurng V; Ross AE; Schaeffer EM; Klein EA; Freedland SJ; Erho N; Yousefi K; Takhar M; Davicioni E; Cooperberg MR; Trock BJ
Eur Urol; 2018 Feb; 73(2):168-175. PubMed ID: 28400167
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate.
Catton C; Gospodarowicz M; Warde P; Panzarella T; Catton P; McLean M; Milosevic M
Radiother Oncol; 2001 Apr; 59(1):51-60. PubMed ID: 11295206
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.
Dal Pra A; Ghadjar P; Hayoz S; Liu VYT; Spratt DE; Thompson DJS; Davicioni E; Huang HC; Zhao X; Liu Y; Schär C; Gut P; Plasswilm L; Hölscher T; Polat B; Hildebrandt G; Müller AC; Pollack A; Thalmann GN; Zwahlen D; Aebersold DM
Ann Oncol; 2022 Sep; 33(9):950-958. PubMed ID: 35636621
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy.
Tsien C; Griffith KA; Sandler HM; McLaughlin P; Sanda MG; Montie J; Reddy S; Hayman JA
Urology; 2003 Jul; 62(1):93-8. PubMed ID: 12837430
[TBL] [Abstract][Full Text] [Related]
20. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
